• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Zahra Mahmoudjafari Previews CAR T Therapies Coming Down the Pipeline

Video

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.

Transcript

What CAR T therapies do you see coming down the pipeline and how do they differ from each other?

That's a loaded question; there's a lot. For the currently approved products, we're learning to use them earlier in lines of care. For the diffuse large B-cell lymphoma population, those indications, and second-line therapy should be coming anytime in the next week to the next couple of months.

Then, we are looking at expanding indications to larger disease states. Obviously, we've had a lot of great approvals with the multiple myeloma products. That recent approval was just on February 28, so I think myeloma is good for a little bit.

In terms of CAR T specifically, for immune effector cells, the bispecifics are the next thing that we're really excited about. We're also looking at allogeneic CAR T products, which are off the shelf, which would really significantly decrease the manufacturing time that we are challenged with at this point.

Related Videos
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Michael Morse, MD, Duke Cancer Center
Dr Chris Pagnani
Screenshot of Angela Jia, MD, PhD, during a video interview
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Screenshot of Alexander Kutikov, MD, during a video interview
Screenshot of Mary Dunn, MSN, NP-C, OCN, RN, during a video interview
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.